Detailed answers about ACADEMY OF DIABETIC & CARDIORENAL MEDICINE LONDON, including incorporation, status, business activity, and accounts information.
When was ACADEMY OF DIABETIC & CARDIORENAL MEDICINE LONDON founded?
ACADEMY OF DIABETIC & CARDIORENAL MEDICINE LONDON was officially incorporated on 13 September 2024 and is registered under company number 15956011. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is ACADEMY OF DIABETIC & CARDIORENAL MEDICINE LONDON?
PRI/LBG/NSC (Private, Limited by guarantee, no share capital, use of 'Limited' exemption). This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations.
What is the current status of ACADEMY OF DIABETIC & CARDIORENAL MEDICINE LONDON?
ACADEMY OF DIABETIC & CARDIORENAL MEDICINE LONDON's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does ACADEMY OF DIABETIC & CARDIORENAL MEDICINE LONDON do?
ACADEMY OF DIABETIC & CARDIORENAL MEDICINE LONDON operates in the following sector: 85590 - Other education n.e.c.. This provides insight into the company's primary business activity and industry focus.
What is ACADEMY OF DIABETIC & CARDIORENAL MEDICINE LONDON's registered address?
The registered office address of ACADEMY OF DIABETIC & CARDIORENAL MEDICINE LONDON is C/O SEDULO OFFICE 605, ALBERT HOUSE 256-260 OLD STREET, LONDON, ENGLAND, EC1V 9DD. This is the official address filed with Companies House for legal and statutory correspondence.
Is ACADEMY OF DIABETIC & CARDIORENAL MEDICINE LONDON financially stable?
Financial accounts for ACADEMY OF DIABETIC & CARDIORENAL MEDICINE LONDON are not currently available. Without filed accounts, it is more difficult to assess the company's financial stability and trading performance.